title: [The role of adjuvant chemotherapy in operable non-small cell lung cancer].
abstract: Postoperative recurrence is the main cause of primary treatment failure in the resectable non-small cell lung cancer (NSCLC). Systematic treatments should be taken to decrease the recurrence. Adjuvant chemotherapy, including neoadjuvant chemotherapy, postoperative adjuvant chemotherapy and targeted therapy, is a widely used in this area. In this review, we summarize the clinical trials and meta-analysis related to the adjuvant chemotherapy and targeted therapy in patients with early stage NSCLC.
authors.affiliation: Depatment of Medical Oncology, Henan Tumor Hosipital, Zhengzhou 450000, China.
authors.forename: Xiangtao
authors.initials: X
authors.lastname: Yan
authors.forename: Hui
authors.initials: H
authors.lastname: Zhu
authors.forename: Huijuan
authors.initials: H
authors.lastname: Wang
authors.forename: Qiming
authors.initials: Q
authors.lastname: Wang
authors.forename: Peng
authors.initials: P
authors.lastname: Li
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Ma
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D011184:Postoperative Period; D057234:Preoperative Period